Parsa Kiai
Known title: DirectorCIK: 0001766850
Parsa Kiai's purchase track record
Parsa Kiai has no open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 8/19/2026 | MED | $1.42M | pending | pending | — |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| MED | ▲ Buy | Open Market | 41,975 | $515K | 8/26/2026 | View on chart |
| MED | ▲ Buy | Open Market | 1,175 | $14K | 8/26/2026 | View on chart |
| MED | ▲ Buy | Open Market | 4,211 | $51K | 8/24/2026 | View on chart |
| MED | ▲ Buy | Open Market | 118 | $1K | 8/24/2026 | View on chart |
| MED | ▲ Buy | Open Market | 41,975 | $487K | 8/20/2026 | View on chart |
| MED | ▲ Buy | Open Market | 1,175 | $14K | 8/20/2026 | View on chart |
| MED | ▲ Buy | Open Market | 799 | $9K | 8/19/2026 | View on chart |
| MED | ▲ Buy | Open Market | 28,538 | $333K | 8/19/2026 | View on chart |
| MED | ▲ Buy | Grant | 11,680 | $0 | 5/26/2026 | View on chart |
| MED | ▲ Buy | Grant | 7,637 | $0 | 5/26/2026 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
No new news for MED in the past week
There are no recent news items specifically about Medifast Inc. in the last seven days. The only recent headlines are about Hormel Foods and Boston Beer, which do not involve Medifast. Therefore, no new developments have been reported for the company itself.
No new news for MED in the past week. There are no recent news items specifically about Medifast Inc. in the last seven days. The only recent headlines are about Hormel Foods and Boston Beer, which do not involve Medifast. Therefore, no new developments have been reported for the company itself.